{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:45:46Z","timestamp":1790419546365,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007231","name":"Cancerf\u00f6reningen i Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007231","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00345-018-2375-7","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T08:41:24Z","timestamp":1529052084000},"page":"155-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8182-3129","authenticated-orcid":false,"given":"Tomas","family":"Thiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotta","family":"Ryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotta","family":"Renstr\u00f6m-Koskela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Steineck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Peter","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra J.","family":"de Verdier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,15]]},"reference":[{"issue":"2","key":"2375_CR1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumours. J Urol 116(2):180\u2013183","journal-title":"J Urol"},{"issue":"6","key":"2375_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","volume":"59","author":"M Babjuk","year":"2011","unstructured":"Babjuk M, Oosterlinck W, Sylvester R et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59(6):997\u20131008","journal-title":"Eur Urol"},{"issue":"4","key":"2375_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639\u2013653","journal-title":"Eur Urol"},{"issue":"3","key":"2375_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013477 (discussion 475\u2013467)","journal-title":"Eur Urol"},{"issue":"3","key":"2375_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/00365590310008037","volume":"37","author":"P Larsson","year":"2003","unstructured":"Larsson P, Wijkstrom H, Thorstenson A et al (2003) A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol 37(3):195\u2013201","journal-title":"Scand J Urol Nephrol"},{"issue":"3 Pt 1","key":"2375_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/S0022-5347(01)67650-X","volume":"153","author":"MA Hudson","year":"1995","unstructured":"Hudson MA, Herr HW (1995) Carcinoma in situ of the bladder. J Urol. 153(3 Pt 1):564\u2013572","journal-title":"J Urol."},{"issue":"2","key":"2375_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0090-4295(99)00463-X","volume":"55","author":"AM Kamat","year":"2000","unstructured":"Kamat AM, Lamm DL (2000) Intravesical therapy for bladder cancer. Urology. 55(2):161\u2013168","journal-title":"Urology."},{"issue":"2","key":"2375_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstrom","year":"2009","unstructured":"Malmstrom PU, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247\u2013256","journal-title":"Eur Urol"},{"issue":"4","key":"2375_CR9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","volume":"63","author":"A Bohle","year":"2004","unstructured":"Bohle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology 63(4):682\u2013686 (discussion 686\u2013687)","journal-title":"Urology"},{"issue":"1","key":"2375_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","volume":"163","author":"F Millan-Rodriguez","year":"2000","unstructured":"Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J (2000) Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163(1):73\u201378","journal-title":"J Urol"},{"issue":"5","key":"2375_CR11","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der MA, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168(5):1964\u20131970","journal-title":"J Urol"},{"key":"2375_CR12","doi-asserted-by":"crossref","unstructured":"Shang PF, Kwong J, Wang ZP et al (2011) Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev (5):CD006885","DOI":"10.1002\/14651858.CD006885.pub2"},{"key":"2375_CR13","doi-asserted-by":"crossref","unstructured":"Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev (3):CD003231","DOI":"10.1002\/14651858.CD003231"},{"issue":"3","key":"2375_CR14","first-page":"499","volume":"19","author":"DL Lamm","year":"1992","unstructured":"Lamm DL (1992) Carcinoma in situ. Urol Clin N Am 19(3):499\u2013508","journal-title":"Urol Clin N Am"},{"issue":"5","key":"2375_CR15","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1080\/21681805.2016.1210672","volume":"50","author":"E Kaasinen","year":"2016","unstructured":"Kaasinen E, Wijkstrom H, Rintala E, Mestad O, Jahnson S, Malmstrom PU (2016) Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. Scand J Urol 50(5):360\u2013368","journal-title":"Scand J Urol"},{"issue":"1","key":"2375_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3109\/00365590903419020","volume":"44","author":"A Thorstenson","year":"2010","unstructured":"Thorstenson A, Schumacher MC, Wiklund NP et al (2010) Diagnostic random bladder biopsies: reflections from a population-based cohort of 538 patients. Scand J Urol Nephrol 44(1):11\u201319","journal-title":"Scand J Urol Nephrol"},{"key":"2375_CR17","unstructured":"International Union against Cancer, Harmer MH, International Union against Cancer (1978) Committee on TNM Classification. TNM classification of malignant tumours, 3rd edn. The Union, Geneva"},{"issue":"7","key":"2375_CR18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0046-8177(99)90153-3","volume":"30","author":"VE Reuter","year":"1999","unstructured":"Reuter VE, Epstein JI, Amin MB, Mostofi FK (1999) The \u201cWHO\/ISUP consensus classification of urothelial (transitional cell) neoplasms\u201d: continued discussion. Hum Pathol 30(7):879\u2013880","journal-title":"Hum Pathol"},{"issue":"10","key":"2375_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.eursup.2008.07.007","volume":"7","author":"R Persad","year":"2008","unstructured":"Persad R, Lamm D, Brausi M et al (2008) Current approaches to the management of non-muscle invasive bladder cancer: comparison of current guidelines and recommendations. Eur Urol Suppl 7(10):637\u2013650","journal-title":"Eur Urol Suppl"},{"issue":"6","key":"2375_CR20","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0302-2838(02)00173-2","volume":"41","author":"JJ Patard","year":"2002","unstructured":"Patard JJ, Rodriguez A, Leray E, Rioux-Leclercq N, Guille F, Lobel B (2002) Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 41(6):635\u2013641 (discussion 642)","journal-title":"Eur Urol"},{"issue":"1","key":"2375_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","volume":"67","author":"P Gontero","year":"2015","unstructured":"Gontero P, Sylvester R, Pisano F et al (2015) Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients. Eur Urol 67(1):74\u201382","journal-title":"Eur Urol"},{"issue":"1","key":"2375_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","volume":"169","author":"O Shahin","year":"2003","unstructured":"Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE (2003) A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169(1):96\u2013100 (discussion 100)","journal-title":"J Urol"},{"issue":"1","key":"2375_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L et al (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guerin. Eur Urol 69(1):60\u201369","journal-title":"Eur Urol"},{"issue":"5","key":"2375_CR24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0090-4295(98)00369-0","volume":"52","author":"J Baniel","year":"1998","unstructured":"Baniel J, Grauss D, Engelstein D, Sella A (1998) Intravesical bacillus Calmette-Guerin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 52(5):785\u2013789","journal-title":"Urology"},{"issue":"2","key":"2375_CR25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0090-4295(99)00116-8","volume":"54","author":"R Hurle","year":"1999","unstructured":"Hurle R, Losa A, Manzetti A, Lembo A (1999) Intravesical bacille Calmette-Guerin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54(2):258\u2013263","journal-title":"Urology"},{"issue":"5","key":"2375_CR26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.eururo.2009.05.047","volume":"57","author":"P Mariappan","year":"2010","unstructured":"Mariappan P, Zachou A, Grigor KM, Edinburgh Uro-Oncology G (2010) Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 57(5):843\u2013849","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-018-2375-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2375-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2375-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T05:48:51Z","timestamp":1569044931000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-018-2375-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["2375"],"URL":"https:\/\/doi.org\/10.1007\/s00345-018-2375-7","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,15]]},"assertion":[{"value":"21 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There were no potential conflicts of interests among the authors of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Research involving human participants was supervised and approved by the Regional Ethics board of the Stockholm County.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human participants"}},{"value":"All the participants in this study gave informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}